title: An in vitro and in vivo study of the α-amylase activity of phaseolamin.
abstract: We evaluated the polypeptide profiles, inhibition of human salivary α-amylase activity, and hemagglutination properties of a commercial phaseolamin sample. We also performed an in vivo assay to investigate the effects of a commercial phaseolamin treatment (100, 500, or 1500 mg/kg) over 20 days on the glycemia, body weight, and serum biochemical parameters (total cholesterol, triglycerides, alanine aminotransferase, and aspartate aminotransferase) of nondiabetic and streptozotocin-induced diabetic rats. The in vitro evaluation showed defined protein profiles, low hemagglutination activity, and high α-amylase inhibition. None of the experimental groups treated with phaseolamin or acarbose showed decreases in body weight. Our data demonstrate that phaseolamin inhibits amylase activity in vitro, reduces blood glucose levels, decreases or attenuates some of the renal and hepatic effects of diabetes in streptozotocin-induced rats, and could therefore have therapeutic potential in the treatment or prevention of the complications of diabetes.
authors.affiliation: 1 Institute of Genetics and Biochemistry, Federal University of Uberlandia , Uberlandia, Brazil.
authors.forename: Neire Moura
authors.initials: NM
authors.lastname: de Gouveia
authors.forename: Fernanda Vieira
authors.initials: FV
authors.lastname: Alves
authors.forename: Fabiana Barcelos
authors.initials: FB
authors.lastname: Furtado
authors.forename: Danielli Luana
authors.initials: DL
authors.lastname: Scherer
authors.forename: Antonio Vicente
authors.initials: AV
authors.lastname: Mundim
authors.forename: Foued Salmen
authors.initials: FS
authors.lastname: Espindola
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000201:enzymology* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D008297:Male; D027805:Phaseolus / Q000737:chemistry; D010936:Plant Extracts / Q000008:administration & dosage* / Q000737:chemistry; D037121:Plant Lectins / Q000008:administration & dosage* / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D000516:alpha-Amylases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D004791:Enzyme Inhibitors; D010936:Plant Extracts; D037121:Plant Lectins; C061510:alpha-amylase inhibitor, Phaseolus vulgaris; D000516:alpha-Amylases
keywords: Phaseolus; carbohydrate blockers; diabetes; serum biochemistry; streptozotocin